What have we learned about lipids and cardiovascular risk from PCSK9 inhibitor outcome trials: ODYSSEY and FOURIER?
Sign Up to like & getrecommendations! Published in 2019 at "Cardiovascular Research"
DOI: 10.1093/cvr/cvy301
Abstract: The role of proprotein convertase subtilisin/kexin Type 9 (PCSK9) in the regulation of the low-density lipoprotein (LDL)-receptor and plasma cholesterol was identified in 2003. This seminal discovery led to the rapid exploitation of PCSK9 as… read more here.
Keywords: learned lipids; lipids cardiovascular; cardiovascular risk; outcome trials ... See more keywords